Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5635815 | 0.72 | TSHR (0.37) | TSHRSMN1; SMN2ADORA1ALDH1A1KDM4E | |
| SCHEMBL5098119 | 0.67 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1KDM4EHSD11B1 | |
| SCHEMBL5139207 | 0.64 | HSD11B1 (0.39) | TSHRSMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL11066997 | 0.62 | MAPT (0.36) | TSHRADORA1ALDH1A1MAPT | |
| SCHEMBL6496549 | 0.62 | SMN1; SMN2 (0.37) | TSHRSMN1; SMN2ADORA1ALDH1A1KDM4E | |
| SCHEMBL27173141 | 0.60 | MEN1 (0.40) | TSHRSMN1; SMN2ADORA1ALDH1A1KDM4E | |
| SCHEMBL5095918 | 0.60 | HSD11B1 (0.51) | L3MBTL1SMN1; SMN2ALDH1A1RAB9AHSD11B1 | |
| SCHEMBL6959750 | 0.58 | — | — | |
| SCHEMBL4872720 | 0.57 | HSD11B1 (0.43) | TSHRSMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL5092143 | 0.56 | HSD11B1 (0.62) | TSHRSMN1; SMN2ALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | HSD11B1, HSD17B1, HSD11B2 | TSHR 2731/4885L3MBTL1 1964/4885SMN1; SMN2 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.